Human platelet lysate to substitute fetal bovine serum in hMSC expansion for translational applications: a systematic review.

Details

Ressource 1Download: 32933520_BIB_6550B617E3D8.pdf (826.29 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_6550B617E3D8
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Human platelet lysate to substitute fetal bovine serum in hMSC expansion for translational applications: a systematic review.
Journal
Journal of translational medicine
Author(s)
Guiotto M., Raffoul W., Hart A.M., Riehle M.O., di Summa P.G.
ISSN
1479-5876 (Electronic)
ISSN-L
1479-5876
Publication state
Published
Issued date
15/09/2020
Peer-reviewed
Oui
Volume
18
Number
1
Pages
351
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
Foetal bovine serum (FBS), is the most commonly used culture medium additive for in vitro cultures, despite its undefined composition, its potential immunogenicity and possible prion/zoonotic transmission. For these reasons, significant efforts have been targeted at finding a substitute, such as serum free-media or human platelet-lysates (hPL). Our aim is to critically appraise the state-of-art for hPL in the published literature, comparing its impact with FBS.
In June 2019 a systematic search of the entire Web of Science, Medline and PubMed database was performed with the following search terms: (mesenchymal stem cells) AND (fetal bovine serum OR fetal bovine calf) AND (human platelet lysate). Excluded from this search were review articles that were published before 2005, manuscripts in which mesenchymal stem cells (MSCs) were not from human sources, and when the FBS controls were missing.
Based on our search algorithm, 56 papers were selected. A review of these papers indicated that hMSCs cultured with hPL showed a spindle-shaped elongated morphology, had higher proliferation indexes, similar cluster of differentiation (CD) markers and no significant variation in differentiation lineage (osteocyte, adipocyte, and chondrocyte) compared to those cultured with FBS. Main sources of primary hMSCs were either fat tissue or bone marrow; in a few studies cells isolated from alternative sources showed no relevant difference in their response.
Despite the difference in medium choice and a lack of standardization of hPL manufacturing, the majority of publications support that hPL was at least as effective as FBS in promoting adhesion, survival and proliferation of hMSCs. We conclude that hPL should be considered a viable alternative to FBS in hMSCs culture-especially with a view for their clinical use.
Keywords
Adipose derived stem cells, Cell therapy, Foetal bovine serum, Human platelet lysate, Mesenchymal stem cells
Pubmed
Web of science
Open Access
Yes
Create date
19/09/2020 11:46
Last modification date
23/11/2022 7:11
Usage data